Company intelligence / Profile preview

Kirovest Pharmaceutical

Ownership: Private
Development stage: Commercial

Overview

Kirovest Pharmaceutical is an Egyptian pharmaceutical manufacturer with a robust product pipeline strategy, currently managing over 60 new products at different stages of regulatory registration. The company focuses on both active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), indicating commercial operations with ongoing development activities. Specific clinical results are not detailed in public sources.

Therapeutic areas: Other
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

Irosanolin

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Kirovest Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kirovest Pharmaceutical.

Explore the full profile